Mendus Q2: Crucial readouts approaching in Q4 - Redeye

Redeye comments on Mendus’ Q2 2022 report, following a quarter in which the company delivered solid final MRD data from ADVANCE II. We believe there exists a solid chance that survival data in Q4 2022E confirms positive MRD data, potentially paving the way for pivotal trials as soon as 2023E. Additionally, we appreciate Mendus having secured financing commitments of up to SEK 250m.

Länk till analysen i sin helhet: https://www.redeye.se/research/853733/mendus-q2-2022-crucial-readouts-approaching-in-q4?utm_source=finwire&utm_medium=RSS